{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:17:12Z","timestamp":1788272232369,"version":"build-2803163510"},"reference-count":25,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-complement factor H antibody- (anti-CFH Ab) associated atypical hemolytic uremic syndrome (aHUS) is a known cause of pediatric complement-mediated thrombotic microangiopathy. In our center, plasma exchange (PEX) until remission paired with immunosuppression continues to be the mainstay of therapy, due to limited access to eculizumab. We wanted to study the long-term outcome of this cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of children (&amp;lt;12 years) with Anti-CFH Ab-associated aHUS admitted between January 2017 and December 2024 at our center. Clinical, laboratory, treatment, and outcome data were retrieved from medical records. The primary outcome was renal recovery, defined as eGFR &amp;gt;90\u2005mL\/min\/1.73\u2005m2 with normal blood pressure, no significant proteinuria, and absence of hematuria at last follow-up or at 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 66 records screened, 40 children were eligible. Median age at presentation was 7 years (interquartile range [IQR] 5,8). Median anti-CFH Ab titer was 306\u2005AU\/mL (IQR 214\u2013426). Low C3 was noted in 55% of subjects. All patients received PEX (median 11 cycles; IQR 7.25, 20) and immunosuppression. Median follow-up was 24 months (IQR 7\u201353). At last follow-up, 21 (52.5%) achieved complete renal recovery, while 19 (47.5%) had CKD stage 2\u20134. Relapse incidence was 7.1 per 100 person-years, usually within 6 months of onset. No baseline clinical, laboratory, or treatment variable except duration of dialysis independently predicted renal recovery. Persistent proteinuria was observed up to 6 months but subsequently improved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PEX paired with immunosuppression remains effective for anti-CFH Ab-associated aHUS, but further studies are needed to refine protocols and evaluate complement inhibitors for improved long-term outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/joneph\/aajag189","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:51:30Z","timestamp":1782388290000},"source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcome of pediatric anti-complement factor H antibody-associated atypical hemolytic uremic syndrome receiving abbreviated plasma exchange: a retrospective study from a single center"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7096-3449","authenticated-orcid":false,"given":"Pujitha","family":"Vallabhaneni","sequence":"first","affiliation":[{"name":"Pediatric Nephrology Unit, Department of Pediatrics, PGIMER , Chandigarh ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4253-3385","authenticated-orcid":false,"given":"Lesa","family":"Dawman","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Unit, Department of Pediatrics, PGIMER , Chandigarh ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Rawat","sequence":"additional","affiliation":[{"name":"Pediatric Allergy Immunology Unit, Department of Pediatrics, PGIMER , Chandigarh ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritambhra","family":"Nada","sequence":"additional","affiliation":[{"name":"Department of Histopathology, PGIMER , Chandigarh ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Pediatric Hematology Unit, Department of Pediatrics, PGIMER , Chandigarh ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thakurvir","family":"Singh","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Unit, Department of Pediatrics, PGIMER , Chandigarh ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Sekar","sequence":"additional","affiliation":[{"name":"Department of Histopathology, PGIMER , Chandigarh ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0918-3056","authenticated-orcid":false,"given":"Karalanglin","family":"Tiewsoh","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Unit, Department of Pediatrics, PGIMER , Chandigarh ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2026090109330285100_aajag189-B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"2026090109330285100_aajag189-B2","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.3389\/fimmu.2019.01282","article-title":"Clinical and immunological profile of anti-factor H antibody associated atypical hemolytic uremic syndrome: a nationwide database","volume":"10","author":"Puraswani","year":"2019","journal-title":"Front Immunol."},{"key":"2026090109330285100_aajag189-B3","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00467-019-04233-7","article-title":"Hemolytic uremic syndrome in a developing country: consensus guidelines","volume":"34","author":"Bagga","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"2026090109330285100_aajag189-B4","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/j.lpm.2011.11.013","article-title":"Management of hemolytic uremic syndrome","volume":"41","author":"Loirat","year":"2012","journal-title":"Presse Med"},{"key":"2026090109330285100_aajag189-B5","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.kint.2024.09.012","article-title":"Outcomes from the international society of nephrology hemolytic uremic syndromes international forum","volume":"106","author":"Kavanagh","year":"2024","journal-title":"Kidney Int."},{"key":"2026090109330285100_aajag189-B6","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1182\/blood.2022018833","article-title":"Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study","volume":"142","author":"Brocklebank","year":"2023","journal-title":"Blood"},{"key":"2026090109330285100_aajag189-B7","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int."},{"key":"2026090109330285100_aajag189-B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2020.152000","article-title":"Anti-complement factor I antibody associated atypical hemolytic uremic syndrome \u2013 a new insight for future perspective!","volume":"225","author":"Govindarajan","year":"2020","journal-title":"Immunobiology"},{"key":"2026090109330285100_aajag189-B9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-1904","article-title":"Clinical practice guideline for screening and management of high blood pressure in children and adolescents","volume":"140","author":"Flynn","year":"2017","journal-title":"Pediatrics"},{"key":"2026090109330285100_aajag189-B10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00467-016-3562-7","article-title":"The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome","volume":"32","author":"Song","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"2026090109330285100_aajag189-B11","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/0886022X.2022.2089167","article-title":"Clinical features of children with anti-CFH autoantibody-associated hemolytic uremic syndrome: a report of 8 cases","volume":"44","author":"Li","year":"2022","journal-title":"Ren Fail."},{"key":"2026090109330285100_aajag189-B12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fimmu.2017.00302","article-title":"Analysis of linear antibody epitopes on factor H and CFHR1 using sera of patients with autoimmune atypical hemolytic uremic syndrome","volume":"8","author":"Trojn\u00e1r","year":"2017","journal-title":"Front Immunol."},{"key":"2026090109330285100_aajag189-B13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1159\/000513009","article-title":"Clinical and genetic characteristics of atypical hemolytic uremic syndrome in children: a Chinese cohort study","volume":"145","author":"Wu","year":"2021","journal-title":"Nephron"},{"key":"2026090109330285100_aajag189-B14","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00467-012-2131-y","article-title":"Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics","volume":"27","author":"Geerdink","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"2026090109330285100_aajag189-B15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4103\/ijn.ijn_484_21","article-title":"Delayed hematological remission predicts poor renal outcome in children with atypical hemolytic uremic syndrome","volume":"33","author":"Singhal","year":"2023","journal-title":"Indian J Nephrol."},{"key":"2026090109330285100_aajag189-B16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00467-020-04751-9","article-title":"Early relapse rate determines further relapse risk: results of a 5-year follow-up study on pediatric CFH-Ab HUS","volume":"36","author":"Hofer","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"2026090109330285100_aajag189-B17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.52547\/ijkd.6507","article-title":"Anti-compliment factor H antibody associated hemolytic uremic syndrome in children with abbreviated plasma exchanges: a 12-month follow-up study","volume":"15","author":"Tiewsoh","year":"2021","journal-title":"Iran J Kidney Dis."},{"key":"2026090109330285100_aajag189-B18","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s00467-024-06279-8","article-title":"Abbreviated protocol of plasma exchanges for patients with anti- factor H associated hemolytic uremic syndrome","volume":"39","author":"Thangaraju","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"2026090109330285100_aajag189-B19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s12098-022-04420-9","article-title":"Infections in critically ill children","volume":"90","author":"Kannan","year":"2023","journal-title":"Indian J Pediatr."},{"key":"2026090109330285100_aajag189-B20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/jca.21711","article-title":"Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: audit of efficacy and safety","volume":"34","author":"Khandelwal","year":"2019","journal-title":"J Clin Apher."},{"key":"2026090109330285100_aajag189-B21","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody\u2013associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol."},{"key":"2026090109330285100_aajag189-B22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.kint.2017.04.028","article-title":"Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland","volume":"92","author":"Brocklebank","year":"2017","journal-title":"Kidney Int."},{"key":"2026090109330285100_aajag189-B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6904858","article-title":"Anti-factor H antibodies in Egyptian children with hemolytic uremic syndrome","volume":"2021","author":"Shawky","year":"2021","journal-title":"Int J Nephrol."},{"key":"2026090109330285100_aajag189-B24","doi-asserted-by":"publisher","first-page":"14389","DOI":"10.3390\/ijms241814389","article-title":"Immunosuppressive therapy of antibody-mediated aHUS and TTP","volume":"24","author":"Kelen","year":"2023","journal-title":"Int J Mol Sci."},{"key":"2026090109330285100_aajag189-B25","doi-asserted-by":"publisher","first-page":"604","DOI":"10.25259\/IJN_140_2025","article-title":"Eculizumab for atypical hemolytic uremic syndrome: guidance for developing countries","volume":"35","author":"Bindal","year":"2025","journal-title":"Indian J Nephrol."}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article-pdf\/doi\/10.1093\/joneph\/aajag189\/70894120\/aajag189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article-pdf\/doi\/10.1093\/joneph\/aajag189\/70894120\/aajag189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:33:08Z","timestamp":1788269588000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article\/doi\/10.1093\/joneph\/aajag189\/8778528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag189","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"aajag189"}}